Related Experiment Videos

Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study

B G Weinshenker1, M Issa, J Baskerville

  • 1Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.

Archives of Neurology
|April 1, 1996
PubMed
Abstract

Insights

Short-term worsening of multiple sclerosis (MS) disability may not predict long-term outcomes. Baseline Expanded Disability Status Scale (EDSS) score and MS duration are key factors for clinical trial design.

Area of Science:

  • Neurology
  • Clinical Trials
  • Multiple Sclerosis Research

Background:

  • Clinical trials for progressive multiple sclerosis (MS) often rely on short-term disability score worsening for power calculations.
  • Clinicians aim to modify long-term MS outcomes, but trial endpoints typically focus on short-term changes (1-3 years).
  • A potential disconnect exists between short-term MS outcomes and long-term prognosis.

Purpose of the Study:

  • To validate existing models that predict the time to reach an Expanded Disability Status Scale (EDSS) score of 6.
  • To identify predictors of short-term outcomes in patients with MS.

Main Methods:

  • Prospective follow-up of 259 patients at the Ottawa Regional Multiple Sclerosis Clinic by a single neurologist.
  • Actuarial analysis was used to determine the time to reach EDSS 6.
  • Changes in EDSS scores were analyzed over a 1- to 3-year follow-up period.

Main Results:

  • The long-term outcome in the Ottawa cohort was more favorable compared to previously published data from London, Ontario.
  • Predictions for time to EDSS 6 did not strongly correlate with the extent of short-term disability worsening.
  • Factors associated with increased short-term worsening included a baseline EDSS score near 4.5 and MS duration under 20 years.

Conclusions:

  • Baseline EDSS score and the duration of MS are critical considerations when designing clinical trials for progressive MS.
  • These factors are important for accurately predicting patient outcomes and ensuring adequate statistical power in trials.

Related Concept Videos